Publications
3 shownNivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with niv...
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
2 and 10 mg/kg Q3W, respectively, over control (P<0.00001 for both comparisons). The 6-month PFS rate was 34% (95% CI 27%-41%) and 38% (95% CI 31%45%) for pembrolizumab 2 and 10...
Frequent Co-Authors
Researcher Info
- h-index
- 3
- Publications
- 3
- Citations
- 4,338
- Institution
- New York University
External Links
Identifiers
- ORCID
- 0000-0001-7088-0742
Impact Metrics
h-index
3
h-index: Number of publications with at least h citations each.